IDEAYA Biosciences Inc. (IDYA) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, IDEAYA Biosciences Inc. (NASDAQ: IDYA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $32.89 (-3.15% 1D, market cap $3.17B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IDYA ranks #469 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IDYA carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -13.8%. By comparison, DYN (Dyne Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.18B) and TLX (Telix Pharmaceuticals Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $3.22B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
Per IDYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001676725), IDEAYA Biosciences Inc. generated $218.7M in revenue (+3024.4% YoY), -$113.7M in net income, and -$73.5M in free cash flow against $1.11B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 21.49 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 38% of 52W Range • RSI-14 at 34.6 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IDYA currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($37.24) and Max Pain ($34.53) forces dealer call-delta covering toward $44.81.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
IDEAYA Biosciences Inc. (IDYA) dropped -3.15% to $32.89, trading at 38% of its 52-week range ($26.81 – $42.68). Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.
IDEAYA Biosciences (IDYA) moved into focus after updated ESMO 2026 data for IDE849 in relapsed small cell lung cancer and neuroendocrine carcinomas, and for darovasertib in metastatic and primary uveal melanoma. Despite
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today announced that, on October 29, 2026, the Compen
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced updated clinical results that show promising anti-tumor activity and preliminary overall survival results for IDE849 (SHR-4849), its investigational antibody-drug c
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering.
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and primary uveal melanoma (U
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and primary uveal melanoma
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IDYA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IDYA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, IDEAYA Biosciences Inc. (IDYA) ranks #469 by composite RQD confidence (45/100, grade D) and #204 by equity capitalization ($3.17B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with IDYA at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IDYA
ACTIVE
IDEAYA Biosciences Inc. | D | 45/100 | — | — | -13.8% | -3.15% | $3.17B | Benchmark Subject |
| DYN Dyne Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | +0.35% | $3.18B | /dyn-vs-idya → |
| TLX Telix Pharmaceuticals Limited | D+ | 54/100 | — | — | — | +2.70% | $3.22B | /tlx-vs-idya → |
| ELVN Enliven Therapeutics Inc. | D- | 40/100 | — | — | -26.2% | +0.67% | $3.30B | /elvn-vs-idya → |
| BHC Bausch Health Companies Inc. | C+ | 69/100 | 21.2x | — | 7.6% | +28.76% | $3.33B | /bhc-vs-idya → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), IDEAYA Biosciences Inc. (IDYA) reported GAAP revenue of $218.7M (+3024.4% vs. FY2024 revenue of $7.0M , and +835.3% cumulative change since FY2023) , GAAP net income of -$113.7M, operating cash flow of -$71.1M, and free cash flow of -$73.5M (+70.8% YoY). On the balance sheet, IDYA closed FY2025 with $1.11B in total assets against $0 in total debt (Altman Z-Score: 21.49, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $218.7M | -$113.7M | -$71.1M | -$73.5M | $1.11B | — |
| FY2024 (FY) | 2024-12-31 | $7.0M | -$274.5M | -$247.6M | -$251.4M | $1.12B | — |
| FY2023 (FY) | 2023-12-31 | $23.4M | -$113.0M | -$115.2M | -$115.2M | — | — |
As of 2026-11-01, IDEAYA Biosciences Inc. (NASDAQ: IDYA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $32.89 (-3.15% 1D, market cap $3.17B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IDYA ranks #469 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IDYA carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -13.8%. By comparison, DYN (Dyne Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.18B) and TLX (Telix Pharmaceuticals Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $3.22B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
Per IDYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001676725), IDEAYA Biosciences Inc. generated $218.7M in revenue (+3024.4% YoY), -$113.7M in net income, and -$73.5M in free cash flow against $1.11B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
IDYA last traded at $32.89 (-3.15% on volume of 1,623,979 shares), positioning the stock -11.68% below its 50-day simple moving average ($37.24) and -3.32% below its 200-day simple moving average ($34.02). Across its 52-week range of $26.81 to $42.68, IDYA sits at the 38.3% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±9.1% ($29.90 to $35.88).
Why IDYA Stock dropped -3.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.